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Cystic Fibrosis as a Disease of Misprocessing of the Cystic Fibrosis
Transmembrane Conductance Regulator Glycoprotein
John R. Riordan
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More than 800 different mutations in the CFTR
(Cystic Fibrosis Transmembrane Conductance Regu-
lator) gene have been identified in cystic fibrosis (CF)
patients. Despite this diversity, most individuals with CF
carry at least one CFTR allele whose product is synthe-
sized but fails to mature or to proceed beyond the en-
doplasmic reticulum (ER) within the cell. These CFTR
disease variants, like the products ofmany othermutated
genes, are not so much broken as bent. The common
DF508 variant, as well as various missense mutations in
nearly all CFTR domains, cause local misfolding and
prevent the protein from attaining its native global con-
formation. Cells detect such improperly folded or as-
sembled proteins and target them for degradation
through a set of processes described as biosynthetic qual-
ity control.
The consequences of failed quality control can be se-
vere. Intra- or extracellular protein aggregates accu-
mulate in several pathological conditions, such as am-
yloid diseases and severe a1-antitrypsin deficiency, and
disrupt cellular and tissue function. However, in the case
of CF, the normal functioning of the ER-retention and
-degradation pathways prevents variant CFTR mole-
cules from reaching the plasma membranes of secreting
and reabsorbing epithelial cells, where CFTR is required
as a regulated chloride channel. The DF508 variant of
CFTR and the products of some other short deletion,
insertion, or missense alleles are mildly temperature sen-
sitive; in cell-culture systems, growth at permissive tem-
peratures and some other experimental manipulations
promote maturation and transport of variant proteins
to the cell surface.
How the ER quality-control apparatus distinguishes
a normal conformation from an abnormal one is un-
known, but, as discussed below, several key interactions
have come to light. Discrete primary-structure motifs
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common to CFTR and other related transporter proteins
may be involved. Nascent CFTR—both in wild-type
form and in disease variants such as DF508—interacts
with multiple molecular chaperones on both sides of the
ER membrane—and probably with the coat proteins of
the secretory vesicles that shuttle cargo proteins from
the ER to the Golgi apparatus and beyond. Because
DF508 and other CFTR variants are potentially func-
tional if they can reach the cell surface, these interactions
are of more than theoretical interest. Treatments that
promote the maturation of misfolded secretory proteins
could prove useful in the management of CF and of
many other heritable diseases.
CFTR Biosynthesis and Intracellular Transport
A defect in the apical chloride permeability of CF epi-
thelial cells was known before the discovery of CFTR,
so the localization of the mature glycoprotein to this site
came as no surprise. Like other mammalian N-linked
glycoproteins, CFTR is synthesized from membrane-
bound ribosomes and is glycosylated cotranslationally
(fig. 1). Following conformational maturation, which in-
volves the completion of secondary-, tertiary-, and (in
the case of multisubunit proteins) quaternary-structure
formation, these proteins become the cargo of COPII
vesicles, which pinch off from the ER (see Nichols and
Ginsburg 1999 [in this issue]). The disease-associated
processing mutants of CFTR fail to complete this ER
export step. Wild-type CFTR molecules, like other
plasma-membrane glycoproteins, continue through the
Golgi apparatus, where they acquire complex oligosac-
charide chains before transiting to the plasmamembrane
through another series of vesicular transport steps. Ma-
ture molecules at the cell surface are much more long-
lived than their precursors ( compared with1T ∼ 16 h
2
), but they undergo further rounds of vesicular traf-1∼ h2
ficking in an endocytotic-exocytotic cycle (Prince et al.
1994) and eventually reach the lysosome, where they are
degraded. Some CFTR missense mutations may affect
passage through later stages of the secretory pathway
or through endocytosis and recycling. However, because
DF508 and other mutants investigated to date are ar-
rested at the early ER stage, most attention is focused
there. The ER-to-Golgi transit step is most commonly
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Figure 1 Fate of CFTR molecules synthesized on ER-associated ribosomes. As the primary structure is formed, the polypeptide is incor-
porated into the ER membrane. Core oligosaccharide chains are attached, to which calnexin binds. In addition, the cytosolic chaperones Hsp70,
Hdj-2, and Hsp90 bind, and ubiquitination may occur. To be exported from the ER compartment in a productive manner via COPII-coated
vesicles (not shown), a degree of higher structure must be achieved. This ATP-dependent conformational maturation is accompanied by dis-
sociation of calnexin and the cytosolic chaperones. Fully folded CFTR is protected from degradation, but molecules that do not attain this
conformation (∼75% of wild-type molecules and ∼100% of DF508 molecules) are substrates of ubiquitinating enzymes (ubc) and are degraded
by the proteasome. As-yet-unidentified proteases may also be involved, since degradation is not completely prevented by proteasome inhibition.
When degradation is blocked or saturated, extensive aggregation of export-incompetent molecules occurs. The export-competent population
travel from the ER through an ERGIC (not shown) to the Golgi apparatus, where complex oligosaccharide chains are completed. Vesicles then
carry the completed molecule from the trans-Golgi network (TGN) to the plasma membrane. Endocytic recycling of this population and
degradation of some internalized protein by lysosomal proteases accounts for the turnover of surface-expressed CFTR.
monitored by SDS-PAGE, by following the addition of
complex oligosaccharide chains to CFTR. The kinetics
of the conversion may also be studied by fluorescence
microscopy in real time by use of CFTR-GFP fusions.
Although most evidence indicates that DF508 CFTR re-
mains in the ER, Gilbert et al. (1998) have recently re-
ported that it reaches the intermediate compartment
(ERGIC) between ER and Golgi (see Nichols and Gins-
burg 1999). When its proteolysis is inhibited, highly ag-
gregated forms follow a separate terminal pathway into
discrete subcellular entities, which have been termed
“aggresomes” (Johnston et al. 1998).
DF508 and Other Processing Mutants
In a seminal paper, Cheng et al. (1990) reported that
DF508 CFTR and several other mutants failed to be fully
glycosylated in COS cells but remained in the ER, where
they were degraded. However, others found that, despite
its defective processing, expression of the DF508 CFTR
molecule in Xenopus oocytes (Drumm et al. 1991), at
reduced temperature or extreme overexpression inmam-
malian cells (Dalemans et al. 1991), confers some meas-
urable regulated chloride-channel activity on transfected
cells. Assuming that these observations are not just ar-
tifacts of the expression systems employed, these studies
indicated that mechanisms that overcome misprocessing
could provide an entre´e for molecular therapeutics.
Immunocytochemical localization of wild-type and
DF508 CFTR in epithelial cells of sweat glands showed
that the mutant protein did not reach the apical
membrane but remained intracellular (Kartner et al.
1992). Because the sweat gland is the only readily ac-
cessible affected tissue in CF patients that is not altered
by the secondary pathological manifestations, it has been
difficult to confirm this clear-cut change in subcellular
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localization in other tissues. However, this aberrant lo-
calization has been observed in primary cultures of air-
way epithelial cells from homozygous DF508 patients
(Yang et al. 1993). Thus, the inability of the DF508
CFTR nascent chain to mature and to be exported from
the ER is almost certainly the basis of much of the
disease.
As was initially noted by Cheng et al. (1990), the
immature core-glycosylated forms of both wild-type and
DF508 CFTR turn over rapidly ( ), and con-11T ∼ h22
version of the wild-type protein to the mature form oc-
curs quite inefficiently. Thus, only ∼25% conversion is
seen in pulse-chase experiments (Ward and Kopito
1994). This proportion of nascent chains achieves a
transport-competent conformation by an ATP-depen-
dent mechanism. The remainder succumbs to degrada-
tion by a pathway insensitive to inhibitors of lysosomal
proteases (Yang et al. 1993; Lukacs et al. 1994). Sub-
sequently, nascent CFTR was the first mammalian-
membrane glycoprotein found to be a substrate for the
cytosolic proteasome (Jensen et al. 1995; Ward et al.
1995). Since then, the ubiquitination-proteasome system
has been demonstrated to be an integral part of the ER
quality-control apparatus that scrutinizes membrane
and secretory proteins (Sommer and Wolf 1997).
Like other aberrant proteins in the early secretory
pathway, nascent CFTR chains that have failed to ma-
ture conformationally may be removed from the ER
membrane before or during proteasomal degradation
(Xiong et al. 1999). The degradation of wild-type CFTR
indicates that it has difficulty achieving a native config-
uration. The advantage of this seemingly wasteful bio-
synthetic process is unclear. Wild-type CFTR is normally
kept unphosphorylated and, hence, inactive in the ER
by phosphatases, but treatment with phosphatase inhib-
itors may allow it to be active and thereby introduce an
anion conductance into the ER membrane. Perhaps the
acute sensitivity to the ubiquitin-proteasome pathway
helps to avoid an uncontrolled ion permeability in the
ER membrane, by providing a backup to the
phosphatases.
The behavior of the DF508 mutant is of primary im-
portance to the disease because it is present on at least
one allele in ∼90% of patients. However, many other
disease-associated mutations, as well as others produced
in vitro for experimental purposes, cause similar mis-
processing. For example, R1066C in the fourth cyto-
plasmic loop of CFTR has been studied extensively in
both the laboratory (Seibert et al. 1996a) and the clinic
(Casals et al. 1997). Like DF508, this variant fails to
mature and causes severe disease. Of 30 disease-asso-
ciated mutations in the four cytoplasmic loops, 18 were
similarly misprocessed (Seibert et al. 1996a, 1996b,
1997), suggesting that missense mutations at virtually
any location in the protein can result in misprocessing.
Other examples are found in cytoplasmic domains and
in membrane-spanning segments. The extracytoplasmic
loops, most of which are very short, may be less crucial
for efficient folding. Nine disease-associated mutations
in these domains have been heterologously expressed,
and all were capable of maturing (M. Ha¨mmerle and
J.R. Riordan, unpublished data).
How Are “Good” and “Bad” Nascent Chains
Distinguished?
Because so many different single-amino-acid substi-
tutions throughout the molecule can cause misprocess-
ing, it is unlikely that discrete sequence motifs that in-
teract with the quality-control machinery have been
altered by each of these mutations. More likely, these
mutations perturb the folding of the polypeptides into
higher-order structures, as suggested by the temperature
sensitivity of DF508 CFTR (Denning et al. 1992). Al-
tered protease sensitivity provides the only direct evi-
dence that immature and mature forms of the molecule
have different conformations (Zhang et al. 1998) and
that DF508 is unable to achieve the latter. The folding
alteration caused by the absence of phe508 has been
extensively studied in an isolated domain from CFTR,
called “NBD1,” and short peptides from within it (Qu
et al. 1997). Thomas et al. (1992) originally found that
a synthetic peptide corresponding to the sequence
around phe508 has less b-structure when that residue is
absent. However, spectroscopic measurements with a
complete isolated recombinant NBD1 do not detect sec-
ondary-structure differences at steady state that can be
ascribed to the absence of phe508. Rather, the kinetics
of refolding of denatured NBD1 appears to be reduced
by this deletion (Qu and Thomas 1996; Qu et al. 1997).
Altered equilibria among competing folding pathways
may account for the primary effect of the phe508 de-
letion on NBD1 and may explain the failure of the whole
multidomain protein to reach its native global config-
uration. Similar local disturbances of folding of NBD1
or of other domains, due to different misprocessing mu-
tations (see, e.g., Seibert et al. 1996a), probably also
perturb the overall assembly.
The distinct proteolysis patterns of CFTR’s immature
and mature forms and the fact that DF508 cannot con-
vert from the former to the latter (Zhang et al. 1998)
raise the central question of how the “correct” overall
conformation of the wild-type nascent chain is distin-
guished from an “incorrect” mutant within the cell.
Perhaps a non-native conformation exposes primary-
structure motifs that are specifically recognized by con-
stituents of quality control or by vesicular transport sys-
tems. Such motifs would be analogous to the KDEL and
KKXX sequences, which are responsible for the locali-
zation of resident ER proteins (Teasdale and Jackson
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1996), or to the recently identified RKR triplet that pre-
vents individual subunits of the KATP channel from leav-
ing the ER separately (Zerangue et al. 1999). Thus, a
negative regulatory mechanism may govern the quali-
ty-control process. Alternatively, positive signals may be-
come exposed when the mature conformations are
achieved. A short diacidic ER export signal has been
identified in VSV-G glycoprotein (Nishimura and Balch
1997), and related sequences could be employed by other
secretory and membrane proteins leaving the ER. It will
be crucial to determine whether (a) mutant nascent
CFTR fails to present a necessary positive signal required
for departure or (b) a negative signal responsible for
retention or retrieval is exposed on the immature
polypeptide.
Which Molecules Recognize Signals Distinguishing
“Good” from “Bad”?
No matter how nascent CFTR identifies itself as com-
petent or incompetent for ER export, it is essential to
identify the molecules involved in their differential rec-
ognition. Logical candidates include molecular chaper-
ones, as well as mediators of vesicular transport or of
ER degradation, which disposes of proteins that are in-
competent for export. Ubiquitination ultimately marks
such proteins as substrates for the proteasome (Ward et
al. 1995) and, possibly, other proteinases (Jensen et al.
1995), but earlier steps in the recognition of these target
proteins are unclear. Molecular chaperones act both to
retain unfolded proteins and to assist their folding, and
nascent CFTR is accessible to chaperones on both sides
of the ERmembrane (fig. 1). Calnexin, an ER-membrane
chaperone, interacts with oligosaccharide chains on the
nascent glycoprotein (Pind et al. 1994). On the cyto-
plasmic side, Hsp70 (Yang et al. 1993) and its cochap-
erone, Hdj-2 (Meacham et al. 1999), and Hsp90 (Loo
et al. 1998) bind to immature, but not to mature, CFTR.
Other chaperones may also be present in the large mul-
timolecular complexes with which nascent CFTR is as-
sociated (Pind et al. 1994). However, all of these inter-
actions occur with both wild-type and mutant nascent
chains. No dramatic differences in the stoichiometry or
the kinetics of chaperone-CFTR interactions have yet
been found. This similarity may reflect only the intrin-
sically inefficient maturation of wild-type CFTR, or it
may suggest that chaperone binding is not central to the
cell’s ability to distinguish normal from variant CFTR.
The COPII coat-protein complex, which coats vesicles
that are destined for delivery to the ERGIC (Aridor et
al. 1998), represents another possible point at which
aberrant structures on secreted proteins may be detected.
We are currently exploring the idea that COPII proteins
interact with positive export signals on nascent CFTR.
Similarly, association with COPI vesicles that are re-
sponsible for retrograde retrieval (Cosson and Letour-
neur 1997) and are mediated by putative negative signals
is also being examined. The relation between the folding
and degradation mechanisms and the export and re-
trieval pathways is not understood for any secretory
molecule, but CFTR is serving to focus research efforts
on this issue.
Misprocessing of Other ATP-binding cassette (ABC)
Transporters
The susceptibility of CFTR to misprocessing raises the
possibility that mutations in other ABC proteins might
also cause them to transit the ER inefficiently. If so,
several clinically important predictions might follow. If
a drug-exporting transporter, such as the P-glycoprotein
(P-gp) could be trapped intracellularly, this ABC protein
would not render the tumor cells drug resistant. Unlike
CFTR, wild-type P-gp matures efficiently (Jensen et al.
1995), but missense mutations in many regions of the
protein cause it to arrest in the ER (Loo and Clarke
1997). Hence, one promising strategy for combating
multidrug resistance might be to promote misprocessing
of the wild-type molecule in tumors. However, some-
what ironically, some drugs that are transported by P-
gp promote the maturation of misprocessed mutants
(Loo and Clarke 1997), perhaps by stabilizing the native
conformation of the transporter. A similar interaction
between CFTR and some ligand might well provide ther-
apeutic benefit to CF patients. Unfortunately, few rea-
gents bind to CFTR with suitable affinity; of those that
do, such as genistein, none have improved the processing
of DF508 CFTR.
The multidrug resistance–related protein (MRP), an-
other transporter protein of the ABC family, also reaches
the surface of some cell types inefficiently. However, in
cells that process CFTR poorly, we have found that wild-
type MRP is efficiently processed (Chang et al. 1997).
Deletion of phe728 in MRP, which corresponds to
phe508 in CFTR, causes MRP to behave essentially the
same as DF508 CFTR; other missense mutations have
similar effects (X.-B. Chang and J.R. Riordan, unpub-
lished observations). The discovery of agents that disturb
the maturation of wild-type MRP might have a major
impact in combating resistance to cancer chemotherapy,
because there are as yet no good “reversers” of MRP-
mediated multidrug resistance, whereas some such drugs
are available to combat the effects of P-gp.
The type 1 sulfonylurea receptor (SUR1), another
ABC protein, combines with a small inwardly rectifying
potassium channel (Kir 6.2, the product of the KCNJ11
gene) to form the oligomeric KATP channel of pancreatic
b-cells (Clement et al. 1997). KATP regulates insulin se-
cretion in response to altered intracellular ATP and ADP
levels. Mutations in both the SUR1 and KCNJ11 genes
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have been found in patients with familial persistent hy-
perinsulinemic hypoglycemia of infancy (PHHI) (Agular-
Bryan and Bryan 1996). As with other multisubunit
membrane proteins, assembly of the two subunits to
form the KATP octamer must occur in the ER for either
to be able to proceed to the cell surface. Recently, a short
sequence motif (RKR) common to the two subunits has
been implicated in the retention of KATP subunits that
are not appropriately coassembled (Zerangue et al.
1999). Failure to form the native quaternary structure
is believed to expose this motif so that it is recognized
by some component responsible for ER retention. The
concept of exposure, in incompleted or imperfectly as-
sembled multisubunit or multidomain proteins, of pri-
mary-structure signals normally masked in completed-
native structures is of fundamental importance in the
understanding of and, potentially, in the modulation of
protein transport through the ER. Missense mutations
in each of these ABC proteins most likely block their
exit from the ER, an effect that may be relevant not just
to CF and PHHI but to various other genetic diseases
as well. A prime candidate is the gene for the retinal rod
transporter, ABC-R, in which many different mutations
have been found in patients with different retinal dis-
orders, including Stargardt disease and some forms of
macular dystrophy (Sun et al. 1999). Since 140 different
ABC protein genes have already been recognized in hu-
mans, it is probable that misprocessing will be a prom-
inent feature of other monogenic or polygenic disorders.
Means of Promotion of Maturation of DF508 CFTR
The most direct means of overcoming the inability of
DF508 CFTR to mature would be to prevent the mis-
folding from occurring. Several agents are known to in-
fluence protein folding, including glycerol and other os-
molytes (Brown et al. 1996) as well as reduced
temperature (Denning et al. 1992). Unfortunately, these
treatments only partially restore maturation and are not
amenable to use in vivo. Other rational approaches that
have been explored include inhibition of ER proteolysis
and modulation of chaperone interactions. Proteasome
inhibitors do slow degradation, but maturation does not
increase concomitantly (Jensen et al. 1995), indicating
that degradation and maturation are not in equilibrium.
Binding to calnexin can be prevented by expression of
an unglycosylated version of CFTR. Similarly, treating
cells with castanosperimine, a glucosidase blocker that
interferes with the processing of N-linked sugars on the
glycoprotein, also completely abrogates the interaction
with calnexin (author’s unpublished data). In neither
case, however, do these treatments increase maturation
of DF508 CFTR. Geldanamycin, a member of the most
specific class of chaperone drugs, prevents binding of
Hsp90 to nascent CFTR, but this treatment strongly
accelerates the degradation of the protein, suggesting
that this chaperone normally promotes maturation
rather than contributing to retention (Loo et al. 1998).
On the other hand, deoxyspergualin, which influences
Hsp70 binding, induces a very-low-level chloride-chan-
nel function at the surface of DF508 CFTR–expressing
cells (Jiang et al. 1998).
There may still be hope that CFTR maturation may
be promoted by manipulation of other chaperones, but
it also appears that the ER quality-control system that
limits the surface expression of CFTR may not be me-
diated primarily by this class of molecules. Any thera-
peutic approach based on augmention of ER export will
require specificity. The most fruitful means of achieving
this may come from identification of positive export sig-
nals or negative retention motifs. It may then become
possible to prevent their recognition, by competitive
mimicry of their structures by small molecules.
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